VACCITECH PLC - AMERICAN DEPOSITARY SHARES

Share · NO0010714785 (XNAS)

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of VACCITECH PLC - AMERICAN DEPOSITARY SHARES

No Price

28.04.2026 14:25

Current Prices from VACCITECH PLC - AMERICAN DEPOSITARY SHARES

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
OSLO BORS	NYKD.OL	NOK	28.04.2026 14:25	3,08 NOK	-0,05 NOK -1,75 %
Düsseldorf	NTASAN85.DUSB	EUR	28.04.2026 06:12	0,25 EUR	-0,07 EUR -22,03 %
Quotrix	NTASAN85.DUSD	EUR	28.04.2026 05:27	0,29 EUR	-0,03 EUR -10,16 %

Share Float & Liquidity

Free Float 52,33 %

Shares Float 170,88 M

Shares Outstanding 326,55 M

Company Profile for VACCITECH PLC - AMERICAN DEPOSITARY SHARES Share

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.